Faehlmann M, Rombo L, Hedman P
Trans R Soc Trop Med Hyg. 1981;75(3):362-4. doi: 10.1016/0035-9203(81)90093-6.
A Swedish tourist who had visited Kenya fell ill with Plasmodium falciparum malaria 11 days after returning home, in spite of taking pyrimethamine (50 mg weekly) as malaria prophylaxis. Chloroquine treatment (25 mg base/kg body-weight) giving serum concentrations of 0.30 mumol/l cleared the patent parasitaemia and the patient recovered. Recrudescence occurred, however, within 42 days. A second chloroquine course (30 mg base/kg) gave serum levels up to 1.28 mumol/l. The patient improved rapidly and remained healthy during 28 days without renewed parasitaemia. Further follow-up for 10 months was uneventful. We consider it urgent to assess chloroquine concentrations in serum in patients being treated for falciparum malaria in order to obtain data on fully effective levels. Ineffective serum levels should be ruled out in cases not responding to chloroquine, especially when chloroquine-resistance is suspected.
一名去过肯尼亚的瑞典游客回国11天后感染了恶性疟原虫疟疾,尽管他服用了乙胺嘧啶(每周50毫克)进行疟疾预防。氯喹治疗(25毫克碱基/千克体重)使血清浓度达到0.30微摩尔/升,清除了明显的寄生虫血症,患者康复。然而,42天内复发。第二个氯喹疗程(30毫克碱基/千克)使血清水平高达1.28微摩尔/升。患者迅速好转,28天内保持健康,未再次出现寄生虫血症。进一步随访10个月无异常情况。我们认为,迫切需要评估接受恶性疟治疗患者的血清氯喹浓度,以便获得关于完全有效水平的数据。对于氯喹治疗无反应的病例,尤其是怀疑有氯喹耐药性时,应排除无效的血清水平。